EU pediatrics rules are top regulatory headache for drug companies; variations and fees close behind
This article was originally published in SRA
Executive Summary
The pediatric medicines legislation is the area in the EU drug regulatory system that companies are most concerned about and believe are of "high-priority" for improvement1.